The agenda includes:
Preparation of positions on the evaluation of drugs:
- Darzalex (daratumumab) under a drug programme “Treatment of patients with newly diagnosed systemic light chain amyloidosis (AL)”,
- Fostex Nexthaler (beclometasone dipropionaate anhydricus + formoterol fumarat dihydricus) for the indications: chronic obstructive pulmonary disease; asthma.
Preparation of a position on the legitimacy of granting reimbursement approval for the medicinal product: Reducto spezial (potassium dihydrogen phosphate, sodium monohydrogen phosphate dihydrate) for the indication: hypophosphatemic rickets.